Quick Takeaways
- WASATCH ADVISORS LP filed SCHEDULE 13G/A for Sangamo Therapeutics Inc Common Stock (SGMO).
- Disclosed ownership: 2.1%.
- Date of event: 30 Sep 2025.
WASATCH ADVISORS LP - 30 Sep 2025 SCHEDULE 13G/A Report for Sangamo Therapeutics Inc Common Stock (SGMO)
- Filing Manager
- WASATCH ADVISORS LP
- Reporting Manager
- Wasatch Advisors LP
- Symbol
- SGMO
- Shares outstanding
- 294,683,714 shares
- Disclosed Ownership
- 6,188,358 shares
- Ownership
- 2.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Nov 2025, 14:34:58 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 12 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"WASATCH ADVISORS LP disclosed 2.1% ownership in Sangamo Therapeutics Inc Common Stock (SGMO) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 12 May 2025.
- Current filing was accepted on 12 Nov 2025, 14:34.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Wasatch Advisors LP | 2.1% | 6,188,358 | 5,587,777 | 0 | Mike Yeates | CEO |